What's new
By:
Filters
Cystic Fibrosis Forum (EXP)

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

Should you be taking Singulair?

N

NoExcuses

New member
<b> Effects on montelukast treatment on clinical and inflammatory variables in patients with CF </b> Stelmach, et al. Annals of Allergy, Astham and Immunology, Volume 95, Number 4, October 2005 pp. 372-380 (9)

In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.

There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.

Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).

Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.ingentaconnect.com/content/acaai/aaai/00000095/00000004/art00014;jsessionid=81puhegbtgno.alice">http://www.ingentaconnect.com/...nid=81puhegbtgno.alice</a>
 
N

NoExcuses

New member
<b> Effects on montelukast treatment on clinical and inflammatory variables in patients with CF </b> Stelmach, et al. Annals of Allergy, Astham and Immunology, Volume 95, Number 4, October 2005 pp. 372-380 (9)

In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.

There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.

Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).

Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.ingentaconnect.com/content/acaai/aaai/00000095/00000004/art00014;jsessionid=81puhegbtgno.alice">http://www.ingentaconnect.com/...nid=81puhegbtgno.alice</a>
 
N

NoExcuses

New member
<b> Effects on montelukast treatment on clinical and inflammatory variables in patients with CF </b> Stelmach, et al. Annals of Allergy, Astham and Immunology, Volume 95, Number 4, October 2005 pp. 372-380 (9)

In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.

There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.

Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).

Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.

<a target=_blank class=ftalternatingbarlinklarge href="http://www.ingentaconnect.com/content/acaai/aaai/00000095/00000004/art00014;jsessionid=81puhegbtgno.alice">http://www.ingentaconnect.com/...nid=81puhegbtgno.alice</a>
 
N

NoExcuses

New member
Montelukast is the chemical name for Singulair.

Every med has a brand name and a chemical name (or generic name).

Do you take Pulmozyme? That's it's brand name. It's chemical name (generic name) is dornase alpha.
 
N

NoExcuses

New member
Montelukast is the chemical name for Singulair.

Every med has a brand name and a chemical name (or generic name).

Do you take Pulmozyme? That's it's brand name. It's chemical name (generic name) is dornase alpha.
 
N

NoExcuses

New member
Montelukast is the chemical name for Singulair.

Every med has a brand name and a chemical name (or generic name).

Do you take Pulmozyme? That's it's brand name. It's chemical name (generic name) is dornase alpha.
 
K

karon72

New member
My daughter takes singulair & it is given ina chewable tablet before bedtime. She has an asthma component to her CF (don't know if that is common or if all CFers have that), but along with Flovent it is used as her controller meds. Also, singulair is wonderful for some allergies. My son started singulair when he was 4. He does not have cf & had battled with colds, bronchitis, walking pnuemonia. It was a lot of secondary respiratory infections from his allergies. He tried other allergies med and they didn't work. He was diagnosed with exercise induced asthma at age 4 and put on singulair. I swear it cured his allergies! He has only been sick with mild colds and the occasional stomach bug a couple of times in the last 6 years! Again, he doesn't have CF, but he was a sick little boy until we put him on singulair.
 
K

karon72

New member
My daughter takes singulair & it is given ina chewable tablet before bedtime. She has an asthma component to her CF (don't know if that is common or if all CFers have that), but along with Flovent it is used as her controller meds. Also, singulair is wonderful for some allergies. My son started singulair when he was 4. He does not have cf & had battled with colds, bronchitis, walking pnuemonia. It was a lot of secondary respiratory infections from his allergies. He tried other allergies med and they didn't work. He was diagnosed with exercise induced asthma at age 4 and put on singulair. I swear it cured his allergies! He has only been sick with mild colds and the occasional stomach bug a couple of times in the last 6 years! Again, he doesn't have CF, but he was a sick little boy until we put him on singulair.
 
K

karon72

New member
My daughter takes singulair & it is given ina chewable tablet before bedtime. She has an asthma component to her CF (don't know if that is common or if all CFers have that), but along with Flovent it is used as her controller meds. Also, singulair is wonderful for some allergies. My son started singulair when he was 4. He does not have cf & had battled with colds, bronchitis, walking pnuemonia. It was a lot of secondary respiratory infections from his allergies. He tried other allergies med and they didn't work. He was diagnosed with exercise induced asthma at age 4 and put on singulair. I swear it cured his allergies! He has only been sick with mild colds and the occasional stomach bug a couple of times in the last 6 years! Again, he doesn't have CF, but he was a sick little boy until we put him on singulair.
 
K

karon72

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>sakasuka</b></i>

<b> Effects on montelukast treatment on clinical and inflammatory variables in patients with CF </b> Stelmach, et al. Annals of Allergy, Astham and Immunology, Volume 95, Number 4, October 2005 pp. 372-380 (9)



In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.



There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.



Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).



Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.



<a target=_blank class=ftalternatingbarlinklarge href="http://www.ingentaconnect.com/content/acaai/aaai/00000095/00000004/art00014;jsessionid=81puhegbtgno.alice">http://www.ingentaconnect.com/...nid=81puhegbtgno.alice</a></end quote></div>

I meant to say thanks for the info!!
 
K

karon72

New member
<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>sakasuka</b></i>

<b> Effects on montelukast treatment on clinical and inflammatory variables in patients with CF </b> Stelmach, et al. Annals of Allergy, Astham and Immunology, Volume 95, Number 4, October 2005 pp. 372-380 (9)



In CF the infallmatory process contributes to progressive lung tissue damage. Cysteinyl leukotrienese have been foudn in the sputum of patients with CF in high concentrations sufficient to cause potent biological effects. Twenty-six patients aged 6 to 18 were recruited to this 20-week, randomized, double-blind, placebo-controlled, crossover trial. Patients received montelukast or placebo for 8 weeks in addition to their regular CF treatment. Compared with placebo use, montelukast treatment significally improved forced expiratory volume in 1 second, peak expiratory flow, and forced expiratory flow between 25% and 75% and decreased cough and wheezing scale scores.



There were no significant changes in vital capacity, thoracic gas volumes, airway resistance, and residual volume after treatment.



Compared with placebo use, montelukast treatment decreased serum and sputum levels of eosinophil cationic protein and IL-8, decreased sputum levels of myeloperoxidase, and increased serium and sputum levels of IL-10 ( P < .001 for all).



Thus, montelukast may have measurable anti-inflammatory properties in patients with CF.



<a target=_blank class=ftalternatingbarlinklarge href="http://www.ingentaconnect.com/content/acaai/aaai/00000095/00000004/art00014;jsessionid=81puhegbtgno.alice">http://www.ingentaconnect.com/...nid=81puhegbtgno.alice</a></end quote></div>

I meant to say thanks for the info!!
 
You must log in or register to reply here.
Top